JenaValve Technology schließt erfolgreich Serie C Finanzierungsrunde mit 62,5 Millionen $ ab

By on Juli 24, 2013

JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has raised $62.5 million in a Series C venture round.
The financing was led by Belgium-based Gimv (GIMB.EN), a publicly traded investment company with more than 30 years of experience in private equity and venture capital. Other new investors include Beijing-based Legend Capital, a venture capital arm of Legend Holdings, Ltd. and an active investor in life sciences as well as Omega Funds, an international healthcare focused investment firm.
Edmond de Rothschild Investment Partners of Paris led the participation by the existing investor group in the Series C round. Other current investors participating in the round included Atlas Venture Fund, NeoMed Management, VI Partners AG and Sunstone Capital A/S.

www.jenavalve.de


Mehr Informationen zu dieser und vielen anderen Transaktionen erhalten Sie HIER


Über 25.000 recherchierte Transaktionen seit 2005 - Legen Sie sich Ihre eigene Datenbank zu!